Niagen Bioscience (NAGE) Total Liabilities (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Total Liabilities of $32.0 million for Q1 2026, up 23.11% year-over-year from $26.0 million in Q1 2025, and up 7.12% quarter-over-quarter from $29.9 million in Q4 2025.
Niagen Bioscience (NAGE) Total Liabilities (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Total Liabilities for 14 consecutive years, with $32.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 23.11% year-over-year to $32.0 million; the TTM figure through Mar 2026 stood at $32.0 million (up 23.11% YoY), while the FY2025 annual figure was $29.9 million, up 34.66% from the prior year.
- Total Liabilities grew to $32.0 million in Q1 2026 per NAGE's latest filing, from $29.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $32.0 million in Q1 2026 and bottomed at $22.2 million in Q3 2024.
- Historically, Total Liabilities has averaged $26.0 million across 5 years, with a median of $26.0 million in 2025.
- Annual changes were most pronounced in 2024 — Total Liabilities fell 16.31% — and 2025, when it surged 34.66%.
- Niagen Bioscience's Total Liabilities stood at $25.4 million in 2022, then climbed by 4.42% to $26.5 million in 2023, then dropped by 16.31% to $22.2 million in 2024, then soared by 34.66% to $29.9 million in 2025, then increased by 7.12% to $32.0 million in 2026.
- Business Quant data shows NAGE's Total Liabilities at $32.0 million in Q1 2026, $29.9 million in Q4 2025, and $27.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 24.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.06 Mn |
| Mar 31, 2026 | 32.00 Mn |
| Dec 31, 2025 | 29.87 Mn |
| Sep 30, 2025 | 27.46 Mn |
| Jun 30, 2025 | 27.33 Mn |
| Mar 31, 2025 | 25.99 Mn |
| Dec 31, 2024 | 22.18 Mn |
| Sep 30, 2024 | 22.15 Mn |
| Jun 30, 2024 | 23.32 Mn |
| Mar 31, 2024 | 25.13 Mn |
| Dec 31, 2023 | 26.51 Mn |
| Sep 30, 2023 | 26.18 Mn |
| Jun 30, 2023 | 26.02 Mn |
| Mar 31, 2023 | 25.75 Mn |
| Dec 31, 2022 | 25.39 Mn |
| Sep 30, 2022 | 24.64 Mn |
| Jun 30, 2022 | 25.84 Mn |
| Mar 31, 2022 | 27.05 Mn |
| Dec 31, 2021 | 26.11 Mn |
| Sep 30, 2021 | 25.00 Mn |